



16 March 2022  
EMA/MB/30014/2022 Adopted  
Management Board meeting of 16-17 March 2022

## Draft agenda for the 115<sup>th</sup> meeting of the Management Board

Held on 16 March 2022, Room 1C/WebEx (15:00 – 18:30)

Held on 17 March 2022, Room 1C/WebEx (09:00 – 16:00)

Chairperson: Christa Wirthumer-Hoche

| Item |   |  |
|------|---|--|
| 1.   | Draft agenda  | For adoption,<br>EMA/MB/30014/2022*                  |
| 2.   | Declarations of competing interests related to the current agenda   | Oral report  |
| 3.   | Election of the Chair of the Management Board<br><b>(in camera to take place on Thursday 17 March at 09:00am CET)</b>       | By ballot  |
| 4.   | Minutes from the 114th meeting, held on 15-16 December 2021 adopted via written procedure                                   | EMA/MB/761948/2021*                                  |
| 5.   | Update on regulatory and coordinating actions arising from the war in Ukraine   | For information                                      |
| 6.   | EMA extended mandate – Regulation (EU) 2022/123   |  |
|      | i. European Commission update on Health Union package   | Oral update  |
|      | ii. EMA update on implementation activities:  |  |
|      | a. Chapter II: Monitoring and mitigating shortages of critical medicinal products and management of major events including: | For information & discussion,<br>EMA/MB/105513/2022; |
|      | o Draft Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) Rules of Procedure                    | For information,<br>EMA/41493/2022;                  |
|      | b. Chapter IV: Monitoring and mitigating shortages of critical medical devices  | For information,<br>EMA/MB/105513/2022;              |



|          |  |  |
|----------|--|--|
|          | <ul style="list-style-type: none"> <li>c. Chapter III: Medicinal products with the potential to address public health emergencies, including: <ul style="list-style-type: none"> <li>o Emergency Task Force (ETF) composition</li> <li>o Draft Emergency Task Force Rules of Procedure</li> </ul> </li> <li>d. Chapter IV: Support for the Expert Panels on medical devices</li> </ul> | <p>For information &amp; discussion, EMA/MB/105513/2022;</p> <p>For adoption, EMA/555794/2021*;</p> <p>For information, EMA/336551/2021;</p> <p>For information, EMA/MB/105513/2022;</p> <p>For information, EMA/MB/105513/2022, EMA/359462/2021</p> |
| 7.       | <p>COVID-19</p> <ul style="list-style-type: none"> <li>• EMA Status Report</li> </ul>  | For information  |
| <b>A</b> | <b>Points for automatic adoption</b>   |  |
| <b>B</b> | <b>Points for discussion</b>   |  |
| B.1      | Highlights of the Executive Director   | Oral report  |
| B.2      | Report from the European Commission  | Oral report  |
| B.3      | EMA Annual Report 2021   | <p>For information, EMA/MB/107705/2022;</p> <p>For adoption, EMA/74495/2022*</p>   |
| B.4      | 2021 EMA Annual Report on Independence   | <p>For information, EMA/MB/149373/2022;</p> <p>For endorsement, EMA/759921/2021*</p>   |
| B.5      | Revised implementing rules to the Fee Regulation as of 1 April 2022  | <p>For information, EMA/MB/407922/2021;</p> <p>For adoption, EMA/MB/408059/2021*</p>   |
| B.6      | Composition of the Paediatric Committee – Joint PDCO/CHMP membership   | <p>For information EMA/MB/64247/2022, Ref. Ares(2017)446809 - 27/01/2017, EMA/64249/2022</p>   |
| B.7      | Report to the Management Board on the implementation of EU IT systems required by the Clinical Trial Regulation  | <p>For information, EMA/MB/64550/2022, EMA/64551/2022</p>  |
| B.8      | Update on Accelerating Clinical Trials in the EU (ACT EU)  | Oral report  |
| B.9      | Update on implementation of Veterinary Medicinal Products Regulation   | Oral report  |
| B.10     | 12th Annual Veterinary MUMS/limited market Report  | <p>For information, EMA/MB/52895/2022;</p> <p>For endorsement, EMA/573681/2021*</p>  |
| B.11     | Big Data Steering Group progress report  | Oral report  |

|          |  |  |
|----------|--|--|
| B.12     | OPEN Pilot: one-year review and recommendations  | For information,<br>EMA/MB/113300/2022;<br>For endorsement,<br>EMA/6881/2022 |
| B.13     | Agile transformation progress update   | For information,<br>EMA/MB/126686/2022                                       |
| B.14     | Stakeholder engagement biennial report: engaging with patients, consumers, healthcare professionals and academia                                 | For information,<br>EMA/MB/138446/2022,<br>EMA/562976/2021*                  |
| <b>C</b> | <b>Points for information only**</b>   |  |
| C.1      | Report on EU Telematics  | For information<br>EMA/MB/116589/2022<br>EMA/116590/2022                     |
| C.2      | Feedback from the Heads of Medicines Agencies  |  |
| C.3      | 2021 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission Reporting period: 1 January to 31 December 2021 | For information,<br>EMA/MB/93986/2022,<br>EMA/719862/2021*                   |
| C.4      | 13th six-monthly report on ex ante and retroactive evaluation of projects for the period 1 July to 31 December 2021                              | For information,<br>EMA/MB/60814/2022,<br>EMA/60815/2022                     |
| C.5      | Preparation for written procedure on opinion on the Agency annual accounts for the financial year 2021   | For information,<br>EMA/MB/34530/2022  |
| C.6      | Outcome of written procedures finalised during the period from 25 November 2021 to 18 February 2022  | EMA/MB/149565/2022*  |
| C.7      | Summary of transfers of appropriations in budget 2021 and 2022   | For information,<br>EMA/MB/58837/2022*                                       |
| C.8      | EMA working document on buildings 2022   | For information,<br>EMA/MB/61235/2022,<br>EMA/61223/2022                     |

\* Documents marked with a star \* are intended for publication on the external website.

\*\* Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.